Cosmo Pharmaceuticals Enters Scale-Up Phase on Strong 2025 Results and AI, Dermatology Pipeline Momentum

An update from COSMO Pharmaceuticals N.V. ( (CH:COPN) ) is now available.

Cosmo Pharmaceuticals reported preliminary 2025 revenues of EUR 104 million, with recurring income driven by GI Genius™ and Winlevi® rising 15% year-on-year to EUR 88 million, and ended the year with more than EUR 128 million in cash and no debt, giving it substantial financial flexibility as it enters a scale-up phase under its Vision 2030 strategy. The company highlighted an operational inflection point with EBITDA at the top end of guidance, the evolution of GI Genius™ into a scalable AI platform including an Apple Vision Pro feasibility study, European regulatory approval for its ColonPRO module, broad international approvals for acne drug Winlevi® ahead of a European launch in 2026, and steady progress in its pipeline for androgenetic alopecia, bile acid diarrhea, distal ulcerative colitis and solid tumors, positioning Cosmo for 2026 value catalysts and potential partnerships that could further strengthen its position in AI-enabled MedTech and dermatology markets.

The most recent analyst rating on (CH:COPN) stock is a Buy with a CHF130.00 price target. To see the full list of analyst forecasts on COSMO Pharmaceuticals N.V. stock, see the CH:COPN Stock Forecast page.

More about COSMO Pharmaceuticals N.V.

Cosmo Pharmaceuticals N.V. is a life-science company focused on AI-enabled medical technology, dermatology, gastrointestinal diseases and contract development and manufacturing (CDMO). The group designs, develops and manufactures advanced solutions such as its GI Genius™ AI endoscopy platform and topical dermatology treatments like Winlevi®, targeting high-growth segments in MedTech AI and specialty pharmaceuticals worldwide.

YTD Price Performance: 3.04%

Average Trading Volume: 51,428

Technical Sentiment Signal: Buy

Current Market Cap: CHF1.83B

For an in-depth examination of COPN stock, go to TipRanks’ Overview page.